Neal Shore, MD, FACS

Neal Shore, MD, FACS, is the medical director for the Carolina Urologic Research Center

Articles

Emerging Trials and the Future of Biomarker-Driven Therapy in Metastatic Castration-Sensitive Prostate Cancer

July 9th 2025

Panelists discuss how emerging trials like AMPLITUDE (PARP inhibitors for BRCA mutations), PSMA-ADDITION (radioligand therapy), and CAPITELLO (AKT inhibitors for PTEN deficiency) are moving the field toward increasingly complex, biomarker-driven treatment selection.

Choosing a Chemotherapy-Based Triplet Regimen in Metastatic Castration-Sensitive Prostate Cancer

July 9th 2025

Panelists discuss how the ARASENSE and PEACE-1 phase 3 trials demonstrated the efficacy of triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and novel antiandrogens, while addressing the ongoing underutilization of intensified treatment approaches.

FDA Approval Insights: Darolutamide for Metastatic Castration-Sensitive Prostate Cancer: With Alicia Morgans, MD, MPH; and Neal Shore, MD, FACS

July 3rd 2025

Drs Morgans and Shore discuss the significance of the FDA approval of darolutamide plus ADT for metastatic castration-sensitive prostate cancer.

Patient Fitness and the Doublet vs Triplet Debate in Metastatic Castration-Sensitive Prostate Cancer

June 30th 2025

Panelists discuss how medical comorbidities, physiologic vs chronologic age, drug interactions, and performance status influence the choice between doublet and triplet therapy regimens.

Personalizing Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

June 30th 2025

Panelists discuss how clinical factors, including disease characteristics (Gleason score, volume, metastatic sites), patient factors (performance status, comorbidities, symptoms), and emerging genomic biomarkers, guide treatment intensification decisions in metastatic castration-sensitive prostate cancer.

AR Pathway Inhibition Refines Prostate Cancer Treatment Strategies: With Neal Shore, MD, FACS

April 7th 2025

Dr Shore discusses advances that have been achieved with AR-directed agents in prostate cancer and considerations for the optimal use of these agents.

Dr Shore on the Importance of Addressing Gaps in Prostate Cancer Management

April 3rd 2025

Neal Shore, MD, FACS, discusses gaps in prostate cancer management and future research directions that may optimize care for high-risk localized disease.

Dr Shore on the Rationale for the Duravelo-2 Trial in Metastatic Urothelial Cancer

November 8th 2024

Neal D. Shore, MD, FACS, discusses the Duravelo-1 and Duravelo-2 trials investigating zelenectide pevedotin in metastatic urothelial carcinoma.

Dr Shore on the Importance of a Multidisciplinary Team in Urologic Oncology

May 3rd 2024

Neal Shore, MD, FACS, discusses the importance of a multidisciplinary team in light of recent developments in urologic oncology.

Dr Shore on Key Clinical Trial Data in Biochemically Recurrent Prostate Cancer

March 11th 2024

Neal Shore, MD, FACS, discusses findings from clinical trials in patients with prostate cancer who experience biochemical recurrence.

Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

March 4th 2024

Our expert panel provide insightful discussion on the power of multidisciplinary expertise in advanced prostate cancer.

Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

March 4th 2024

Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistant prostate cancer.

Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

February 26th 2024

This segment delves into targeting the androgen receptor pathway and conquering treatment resistance for potential breakthroughs in managing advanced prostate cancer.

Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

February 26th 2024

Expert perspectives on androgen receptor signaling and its role in fueling prostate cancer metastasis along with a whiteboarding animation depicting this process.

Treatment Selection in Metastatic and Castration Resistant Prostate Cancer Optimizing Outcomes and Preserving Patient Quality of Life

February 19th 2024

Drs. Shore & McKay discuss treatment selection for metastatic & castration-resistant prostate cancer, the current landscape, and key factors guiding personalized treatment decisions.

Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

February 19th 2024

GU medical oncologist Dr. Rana McKay and urologist Dr. Neal Shore explore how predictive biomarkers and genetic testing are informing risk assessment and guiding personalized treatment decisions in clinical practice

Dr Shore on the Implications of the FDA Approval of Enzalutamide for nmCSPC

February 16th 2024

Neal Shore, MD, FACS, discusses the implications of the FDA approval of enzalutamide for patients with nonmetastatic castration-sensitive prostate cancer.

Dr Shore on the Background and Outcomes of the EMBARK Trial in nmCSPC

February 15th 2024

Neal Shore, MD, FACS, discusses the phase 3 EMBARK study of enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.

Optimizing Care of Patients With Advanced Prostate Cancer: Conclusion

February 9th 2024

Summarizes the main points and benefits of multidisciplinary prostate cancer care.

Clinical Case 4: Radiation Therapy

February 2nd 2024

Covers key factors in deciding on radiation treatment.